フルラゼパム

￥8920 - ￥20900

化学名フルラゼパム

英語名FLURAZEPAM

CAS番号17617-23-1

分子式C21H23ClFN3O

分子量387.88

EINECS241-591-7

MDL NumberMFCD00057324

别名

7-クロロ-1-[2-(ジエチルアミノ)エチル]-5-(2-フルオロフェニル)-1,3-ジヒドロ-2H-1,4-ベンゾジアゼピン-2-オン

1-[2-(ジエチルアミノ)エチル]-5-[2-フルオロフェニル]-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン

1-[2-(ジエチルアミノ)エチル]-5-(2-フルオロフェニル)-7-クロロ-1H-1,4-ベンゾジアゼピン-2(3H)-オン

more

価格 2 物価

生産者	包装単位	価格	製品説明
富士フイルム和光純薬株式会社(wako) W01W0106-0380	500mg	￥20900	フルラゼパム Flurazepam
Sigma-Aldrich Japan F-003	1ml	￥8920	フルラゼパム溶液 Flurazepam solution

生産者

包装単位

価格

製品説明

富士フイルム和光純薬株式会社(wako)

W01W0106-0380

500mg

￥20900

フルラゼパム
Flurazepam

Sigma-Aldrich Japan

F-003

1ml

￥8920

フルラゼパム溶液
Flurazepam solution

プロパティ

安全情報

説明

Flurazepam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam

融点	77-82°
沸点	551.4±50.0 °C(Predicted)
比重(密度)	1.2089 (estimate)
闪点	9℃
貯蔵温度	2-8°C
溶解性	45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <6 mg/mL
酸解離定数(Pka)	pKa 1.90±0.05(H2O) (Uncertain);8.16±0.05 (Uncertain)
外見	solid
色	light yellow
EPAの化学物質情報	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro- (17617-23-1)

フルラゼパム

プロパティ

安全情報

説明

関連商品価格

関連製品価格